Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome

Launched by QUEEN'S MEDICAL CENTER · Feb 22, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how an intravaginal lactic acid gel, specifically looking at the contraceptive method Phexxi, may change the balance of bacteria in the vagina. Researchers believe that using Phexxi regularly might help increase the number of good bacteria that produce lactic acid, which could help prevent recurring infections like bacterial vaginosis (BV) and yeast infections.

To be eligible for this study, participants need to be women aged 18 to 54 who are pre-menopausal and can read and speak English. They should have had at least two episodes of BV or yeast infections in the past year that required treatment. Unfortunately, women who are pregnant, post-menopausal, or currently have a urinary tract infection (UTI) cannot participate. Those who join can expect to use the gel and share their experiences, contributing valuable information that may help improve treatment for these common conditions in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18-54
• • Female
• • Pre-menopausal
• • Can speak and read in English
• • Displays capacity for informed consent
• • Has had 2 or more documented and/or self-reported episodes of symptomatic BV or candida infection in the last year, requiring, over-the-counter or prescription treatment
• Exclusion Criteria:
• • Pregnant or trying to become pregnant
• • Post-menopausal
• • Using NuvaRing device
• • A past medical history of kidney disease, recurrent UTI, and/or urinary tract abnormalities
• • Current UTI
• • Using Phexxi as a contraceptive during the collection period of the study